TABLE 1.

FTLD-U Patients Used in This Study

	Case no.	Sex	Age	Duration	FH	26/132/164	244	137/471
Type 1	1	F	62	5	NR	Yes	Yes	No
	2	M	71	8	NR	Yes	Yes	No
	3	M	92	3	NR	Yes	Yes	No
	4	M	77	12	NR	Yes	Yes	No
	5	F	69	6	Yes§	Yes	Yes	No
	6	M	77	NR	NR	Yes	Yes	No
	7	F	76	11	NR	Yes	Yes	No
	8	F	68	7	NR	Yes	Yes	No
	9	M	64	10	NR	Yes	Yes	No
	10	F	81	2	NR	Yes	Yes	No
	11	M	54	7	NR	Yes	Yes	†
Type 2	12*	M	57	3	Yes§	No	†	Yes
	13*	M	54	2	NR	No	†	Yes
	14	F	54	7	Yes‡	No	†	Yes
	15	F	61	4	Yes§	No	†	Yes
	16*	M	67	10	Yes‡	No	No	Yes
	17	M	41	6	Yes‡	No	No	Yes
Type 3	18	F	NR	NR	NR	No	No	No
	19	F	75	3	NR	No	No	No
	20	F	62	5	Yes‡	No	No	No
	21*	M	65	6	Yes§	No	No	No
	22*	F	79	5	Yes‡	No	No	No
	23	F	76	7	Yes§	No	No	No
	24	F	77	11	Yes‡	No	No	No
	25	F	69	7	Yes§	No	No	No
	26	M	55	2	NR	No	No	No
	27	F	73	6	Yes‡	No	No	No
	28	M	76	7	NR	No	No	No
	29*	F	63	11	NR	No	No	No
	30	F	49	3	Yes§	No	No	No
	31	F	68	9	NR	No	No	No
	32*	M	59	10	NR	No	No	No
	33*	M	48	2	NR	No	No	No
	34*	F	53	2	NR	No	No	No
	35*	M	53	3	NR	No	No	No
	36	F	72	3	NR	No	No	No

Frontotemporal degeneration with ubiquitin-positive inclusion (FTLD-U) cases used in this study are numbered in the left-most column. Indicated is the ability of mAbs 26/132/164, 244, and 137/471 to immunohistochemically stain pathological inclusions in the FTLD-U cases. Sections of frontal cortex and hippocampus were examined from all of the FTLD-U cases with all of the mAbs, and temporal cortex and striatum were additionally examined in some of the cases for confirmation of the results. Disease duration and age are given in years. M, male; F, female; FH, family history; NR, not recorded. 

^*Cases that exhibited MND in addition to dementia. 

^†Cases in which the mAbs detected only a small percentage of the ubiquitin-positive inclusions. 

^‡Two or more first degree relatives with dementia or MND. 

^§One first degree relative or two or more second degree relatives with dementia or MND.